DKD patients were more frequently under SGLT-2 inhibitors treatment (50% vs. 23%; p = 0.03) and statins (97% vs.46.1%; p = 0.01), while no differences were observed for other therapeutics. Here, SLC5A2 is linked to diabetic kidney disease.